Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19483163 | 1.00 | ESR2 (0.36) | ESR2HSD11B1ALDH1A1TDP1 | |
| SCHEMBL15134104 | 0.79 | HSD11B1 (0.37) | ESR2HSD11B1ALDH1A1TDP1 | |
| SCHEMBL16449045 | 0.79 | ALDH1A1 (0.36) | ALDH1A1TDP1 | |
| SCHEMBL15132662 | 0.78 | HSD11B1 (0.39) | ESR2HSD11B1ALDH1A1TDP1 | |
| SCHEMBL12384745 | 0.77 | ALDH1A1 (0.39) | ESR2HSD11B1ALDH1A1TDP1 | |
| SCHEMBL13900364 | 0.77 | ALDH1A1 (0.39) | ESR2HSD11B1ALDH1A1TDP1 | |
| SCHEMBL10013221 | 0.77 | ALDH1A1 (0.39) | ESR2HSD11B1ALDH1A1TDP1 | |
| SCHEMBL23220026 | 0.76 | ALDH1A1 (0.31) | ALDH1A1TDP1 | |
| SCHEMBL19454847 | 0.75 | ALDH1A1 (0.33) | ALDH1A1TDP1 | |
| Terpin SCHEMBL5377815 | 0.75 | TRPA1 (0.40) | ESR2HSD11B1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022261777-A1 | USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS FOR TREATING CANCER | REPARE THERAPEUTICS INC. (CA) | 2022-12-22 | — | — | WO | disclosed |
| US-20220185809-A1 | SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2022-06-16 | — | — | US | disclosed |
| US-20210177856-A1 | USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2021-06-17 | — | — | US | disclosed |
| WO-2021119523-A1 | USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2021-06-17 | — | — | WO | disclosed |
| WO-2008130581-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177856-A1 | USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS | ATR, MRE11, PARP2 | ESR2 2257/4885HSD11B1 3614/4885ALDH1A1 4193/4885 |
| US-20220185809-A1 | SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | ESR2 4134/4885HSD11B1 4400/4885ALDH1A1 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.